Whalen Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Whalen Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$398K	Sell	11,737 -743	-6%	-$24.7K	0.18%	136
2026 Q1	$376K	Sell	12,480 -1,333	-10%	-$42.9K	0.2%	132
2025 Q4	$431K	Sell	13,813 -11,643	-46%	-$287K	0.23%	129
2025 Q3	$514K	Buy	25,456 +10,659	+72%	+$187K	0.3%	76
2025 Q2	$248K	Sell	14,797 -11,495	-44%	-$185K	0.16%	178
2025 Q1	$404K	Buy	+26,292	New	+$470K	0.27%	85

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Whalen Wealth Management's TEVA Position: Q2 2026 in Review

Whalen Wealth Management reduced its Teva Pharmaceuticals (TEVA) stake by 6% in Q2 2026, selling an estimated $24.7K and leaving 11,737 shares worth $398K. The position accounts for 0.18% of the portfolio, ranked #136.

Whalen Wealth Management first reported a position in TEVA in Q1 2025 and has held it in 6 quarters since. The position peaked at $514K in Q3 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Whalen Wealth Management held 11,737 shares of Teva Pharmaceuticals worth $398K as of Q2 2026.
Whalen Wealth Management sold 743 Teva Pharmaceuticals shares in Q2 2026, an estimated $24.7K.
Teva Pharmaceuticals made up 0.18% of Whalen Wealth Management's portfolio in Q2 2026, its #136 holding.
Whalen Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Whalen Wealth Management's Teva Pharmaceuticals position peaked at $514K in Q3 2025.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Whalen Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.